title: Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.
abstract: Angiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous non-small cell lung cancer patients. This review focuses first on the data from clinical trials available to date regarding efficacy and safety of chemotherapy plus bevacizumab. This review then highlights the current remaining questions related to the use of this drug in daily practice and how the patients might be clinically and radiologically selected. Finally, this review explores the future directions for bevacizumab development in nonsquamous non-small cell lung cancer and for a biological selection of patients with research on predictive biomarkers.
authors.affiliation: Aix Marseille University - Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, INSERM U911 CRO2, Marseille, France laurent.greillier@ap-hm.fr.
authors.forename: Laurent
authors.initials: L
authors.lastname: Greillier
authors.affiliation: Aix Marseille University - Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, INSERM U911 CRO2, Marseille, France.
authors.forename: Pascale
authors.initials: P
authors.lastname: Tomasini
authors.affiliation: Aix Marseille University - Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, INSERM U911 CRO2, Marseille, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Barlesi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: angiogenesis; bevacizumab; lung neoplasms; vascular endothelial growth factor